Cargando…
TP53 mutation variant allele frequency is a potential predictor for clinical outcome of patients with lower-risk myelodysplastic syndromes
TP53 mutations are frequently detected in patients with higher-risk myelodysplastic syndromes (MDS); however, the clinical impact of these mutations on the disease course of patients with lower-risk MDS is unclear. In this study of 154 lower-risk MDS patients, TP53 mutations were identified in 13% o...
Autores principales: | Belickova, Monika, Vesela, Jitka, Jonasova, Anna, Pejsova, Barbora, Votavova, Hana, Merkerova, Michaela Dostalova, Zemanova, Zuzana, Brezinova, Jana, Mikulenkova, Dana, Lauermannova, Marie, Valka, Jan, Michalova, Kyra, Neuwirtova, Radana, Cermak, Jaroslav |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5094999/ https://www.ncbi.nlm.nih.gov/pubmed/27167113 http://dx.doi.org/10.18632/oncotarget.9200 |
Ejemplares similares
-
DNA repair gene variants are associated with an increased risk of myelodysplastic syndromes in a Czech population
por: Belickova, Monika, et al.
Publicado: (2013) -
Differential Expression of MicroRNAs in CD34+ Cells of 5q- Syndrome
por: Votavova, Hana, et al.
Publicado: (2011) -
Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients
por: Votavova, Hana, et al.
Publicado: (2021) -
Circulating Small Noncoding RNAs Have Specific Expression Patterns in Plasma and Extracellular Vesicles in Myelodysplastic Syndromes and Are Predictive of Patient Outcome
por: Hrustincova, Andrea, et al.
Publicado: (2020) -
RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS
por: Kaisrlikova, Monika, et al.
Publicado: (2022)